These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Whole-exome sequencing-based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma. Bu Y; Huang R; Gao J; Qu W; Fu X; Liu W; Ding Z; Zhou J; Fan J; Wang X; Chen D; Tang Z Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13901. PubMed ID: 38843867 [TBL] [Abstract][Full Text] [Related]
68. Frequent activating GNAS mutations in villous adenoma of the colorectum. Yamada M; Sekine S; Ogawa R; Taniguchi H; Kushima R; Tsuda H; Kanai Y J Pathol; 2012 Sep; 228(1):113-8. PubMed ID: 22374786 [TBL] [Abstract][Full Text] [Related]
69. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct. Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513 [TBL] [Abstract][Full Text] [Related]
70. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286 [TBL] [Abstract][Full Text] [Related]
71. [The activating GNAS mutation : A survey of fibrous dysplasia, its associated syndromes, and other skeletal and extraskeletal lesions]. Ostertag H; Glombitza S Pathologe; 2018 Mar; 39(2):146-153. PubMed ID: 29488004 [TBL] [Abstract][Full Text] [Related]
72. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Ronchi CL; Peverelli E; Herterich S; Weigand I; Mantovani G; Schwarzmayr T; Sbiera S; Allolio B; Honegger J; Appenzeller S; Lania AG; Reincke M; Calebiro D; Spada A; Buchfelder M; Flitsch J; Strom TM; Fassnacht M Eur J Endocrinol; 2016 Mar; 174(3):363-72. PubMed ID: 26701869 [TBL] [Abstract][Full Text] [Related]
73. Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. Collins MT; Sarlis NJ; Merino MJ; Monroe J; Crawford SE; Krakoff JA; Guthrie LC; Bonat S; Robey PG; Shenker A J Clin Endocrinol Metab; 2003 Sep; 88(9):4413-7. PubMed ID: 12970318 [TBL] [Abstract][Full Text] [Related]
74. Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum. Matsubara A; Ogawa R; Suzuki H; Oda I; Taniguchi H; Kanai Y; Kushima R; Sekine S Br J Cancer; 2015 Apr; 112(8):1398-404. PubMed ID: 25867268 [TBL] [Abstract][Full Text] [Related]
75. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Tabareau-Delalande F; Collin C; Gomez-Brouchet A; Decouvelaere AV; Bouvier C; Larousserie F; Marie B; Delfour C; Aubert S; Rosset P; de Muret A; Pagès JC; de Pinieux G Mod Pathol; 2013 Jul; 26(7):911-21. PubMed ID: 23370769 [TBL] [Abstract][Full Text] [Related]
76. Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. Tirosh A; Jin DX; De Marco L; Laitman Y; Friedman E Genes Chromosomes Cancer; 2020 Sep; 59(9):503-516. PubMed ID: 32337806 [TBL] [Abstract][Full Text] [Related]
77. Three intragenic suppressors of a GTPase-deficient allele of GNAS associated with McCune-Albright syndrome. Turcic K; Tobar-Rubin R; Janevska D; Carroll J; Din E; Alvarez R; Haick J; Pals-Rylaarsdam R J Mol Endocrinol; 2014 Jun; 52(3):321-31. PubMed ID: 24850831 [TBL] [Abstract][Full Text] [Related]
78. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401 [TBL] [Abstract][Full Text] [Related]
79. Identification of GNAS Variants in Circulating Cell-Free DNA from Patients with Fibrous Dysplasia/McCune Albright Syndrome. Roszko KL; Guthrie L; Li X; Collins MT; de Castro LF; Boyce AM J Bone Miner Res; 2023 Mar; 38(3):443-450. PubMed ID: 36593655 [TBL] [Abstract][Full Text] [Related]
80. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J Nat Commun; 2013; 4():2218. PubMed ID: 23887712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]